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Introduction
Glioblastoma multiforme (GBM) remains the most common primary brain tumor. The core of standard of care for newly diagnosed glioblastoma was established in 2005 1, 2 and includes maximal safe surgical resection followed by radiation and temozolomide, with subsequent temozolomide chemotherapy with or without tumor-treating fields. 3 However, nearly all patients experience recurrence and criteria for selecting second-line therapy are less clear. 4 Management options for recurrent disease that have been limited, have been recently enhanced through the advent of targeted therapies. 5, 6 One of these treatment option at recurrence in some countries is bevacizumab (BV), an inhibitor of vascular endothelial growth factor developed to block angiogenesis. 7 The noncomparative randomized phase II, multicenter, open-label BRAIN trial (AVF3708g) investigating bevacizumab plus irinotecan versus bevacizumab alone 8, 9 contributed to accelerated FDA approval of bevacizumab (Avastin ® , Genentech) for treatment of recurrent glioblastoma in 2009. Despite its current US approval for treatment of recurrent glioblastoma, phase II and III clinical trials for patients with recurrent glioblastoma, 10 as well as 2 recent phase III randomized clinical trials for patients with newly diagnosed glioblastoma 5, 11 showed no advance in overall survival (OS) with the addition of bevacizumab to standard therapy. While some patients do appear to have symptomatic improvement from bevacizumab (BV) therapy, its value for treating the tumor is less clear. It can be assumed that there is a patient population with a meaningful clinical benefit, given that the demonstrated activity of bevacizumab evidenced by impact on imaging-based endpoints. [12] [13] [14] Thus, identifying those subjects who are likely to respond or not respond is essential for the best management of glioblastoma patients.
Conventional MR imaging (T1, T2, contrast enhancement) as a standard imaging method for assessing response for glioblastomas has shown to be not always able to accurately assess tumor response.
In particular, anti-angiogenic agents often cause improvement in blood-brain barrier (BBB) disruption and thus reduces contrast enhancement and edema, even when the tumor burden and viability is not impacted.
5,
6, 10 Development of imaging biomarkers that could anticipate response to therapy, have substantial
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In this paper, we used the novel imaging methods, along with machine learning, to assess the usefulness of the combination of Apparent Diffusion Coefficient (ADC) and dynamic-susceptibility contrast (DSC) perfusion MRI-based measurements to predict which patients with recurrent glioblastoma might respond to BV with respect to both progression free and overall survival.
Methods

Patient Selection
After obtaining Institutional Review Board approval, we conducted a retrospective analysis of patients with recurrent glioblastoma treated at our institution from 2008 to 2016. A total of 54 consecutive patients who met the following criteria were identified and included in the study: (a) age of at least 18 years, (b) histologically confirmed contrast-enhancing glioblastoma based on the WHO histological grading system, (c) first recurrence of the tumor defined based on the updated RANO-criteria, 15 , 16 never exposed to any other antiangiogenic therapy, after initial treatment according to current standard of care therapy (maximal safe surgical resection > 90% of tumor confirmed by postoperative MRI within 48h after surgery, radiation therapy, and concomitant and adjuvant chemotherapy with temozolomide, (d) bevacizumab (Avastin ® , Roche; 10mg/kg body weight every 2 weeks intravenously) as second-line mono-therapy of the recurrent glioblastoma, (e) MRI examination including diffusion and DSC perfusion images less than 3 weeks prior to switch to BV therapy, and at least 8 weeks between completion of radiotherapy and initiation of BV-therapy, (f) if receiving corticosteroids, stable or decreasing steroid dose for at least 5 days prior to the baseline MRI scan, (g) baseline Karnofsky performance status ≥ 70, (h) ; follow-up of at least one year or to time of death as well as clinical status during follow-up to allow assessment of PFS6. Of note, BV had to be administered because of tumor progression on temozolomide, not for the purpose of reducing edema such as in steroid-resistant edema.
Patients were excluded from this study if (a) a repeat surgery was performed before initiation of treatment or between the baseline and first follow-up imaging evaluation, (b) there was a recurrence 3 months or less from the end of radiation therapy to avoid involving cases with pseudoprogression, (c) MR images were of insufficient quality due to motion artifacts and/or due to missing advanced MR-sequences, (c) other or combined anti-angiogenic agents were applied.
Response Criteria
We identified 54 subjects that met all above-mentioned criteria. Twenty-three (23) of these 54 patients did not progress within 6 months of initiating BV therapy based on clinical as well as radiologic assessment (including in-depth image review by senior consultant) and were referred to as 'responders' / 'Long PFS6. Of note, twenty-two of the 54 subjects survived more than 12 months after initiating therapy, and these were referred to as 'OS Long'. The time periods for separating long and short are commonly used for both PFS6 and OS, and also divided our subjects into approximately equal groups.
Image processing
All images were retrieved from our clinical image archive, local identifiers were replaced with study identifiers, and stored in our research management system. 17 The T1 post-contrast images were processed with N4 bias correction 18 and intensity normalized. The contrast-enhancing region of interest (CEROI) was manually delineated by an expert without knowledge of the patient response status utilizing ITK snap. 19 The CEROI included the enhancing part of the tumor but did not include scar tissue or vessels.
The MR images on all patients were acquired with either 1.5T or 3T scanners for clinical care purposes. The diffusion-weighted images were all acquired with B=1000, a 128x128 matrix that covered the whole brain (typically 22-24cm) with a slice thickness of 5mm. Apparent Diffusion Coefficient (ADC) maps were calculated from diffusion weighted trace images. These were then registered to the T1 weighted post-contrast images using ANTs. 20 We calculated the mean, median, 95 th and 20 th percentile values for ADC pixels corresponding to the CEROI, referred to as ADCmn, ADCmed, ADC95, ADC20.
We computed relative cerebral blood volume (rCBV), K2, and Peak Signal Recovery (PSR) images from the dynamic susceptibility contrast (DSC) source images. 21 The dynamic susceptibility contrast (DSC)
images were acquired with a 128x128 matrix to cover the brain, and with 10-12 slices that were 5mm thick with 1mm gap, to cover the tumor. The DSC images were obtained using a spin-echo echo-planar sequence with axial orientation and TR/TE/FA of 2217 to 2225 ms/60 ms/90 deg. A gadolinium bolus of 0.1mmol was injected followed by 20cc saline, with the bolus beginning 10 seconds after the beginning of the acquisition (which allows establishment of baseline intensity).
The DSC acquisitions and corresponding maps were registered to the T1-post contrast images also using ANTs. 20 A reference white matter area was created at a location corresponding to the CEROI but in the opposite hemisphere white matter when possible; else the opposite hemisphere on the same slice where white matter appeared normal. Each pixel in the CBV image was divided by the mean value of the white matter region to produce the rCBV image. We calculated the mean, median and the 95 th percentile intensity on the rCBV image for the CEROI.
The K2 image, computed as the slope of the baseline after the bolus peak, reflects the slow leakage of contrast material into tissue and is somewhat analogous to Ktrans. Finally, the Peak Signal Recovery, representing the fraction of baseline intensity versus the maximum signal loss for the enhancing tissue, was also calculated. An example of the T1 image and the corresponding ADC and rCBV images with CEROI is shown in Figure 1 .
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Machine Learning
We then trained 6 different classifiers for predicting both OS (short vs long) and for PFS6 (short vs long): Gradient Boosted (GB), 22 support vector machine (SVM), 23 decision tree classifier (DT), 24 k- 25 passive aggressive classifier (PAC), 26 and logistic regression (LR). 27 These classifiers were selected because they represent a wide variety of classifier styles and so if they had similar performance, it helps to assure that results are robust.
A 3 fold stratified cross validation 28 was used in order to train and select the best classifier from the six considered in the study. The best classifier was that with the highest mean area under the receiver operating characteristic (ROC) curve for the 3 folds. The parameters of each classifier were also estimated utilizing grid search. The parameters include the k value for the KNN classifier, the and C for the SVM classifier as well as the number of estimators and the criterio used in the DT.
The sensitivity, specificity and overall accuracy were calculated. The ROC Curve that represents the overall performance of the system using the selected criteria was created to identify the point on that curve that had 100% sensitivity and a point where there was 100% specificity. These 2 points represent thresholds for classifying those highly likely to respond and also those highly likely to not respond.
Results
Among all included 54 subjects, 23 were 'responders' meaning that they did not meet criteria for progression at 6 months, and 22 were 'long survivors' meaning that they lived more than 1 year after being started on BV. We found that diffusion and perfusion imaging using an SVM was able to identify the imaging properties of subjects either highly likely to not progress within 6 months (PFS6) and those highly likely to progress These results are listed in Table 1 . If the threshold of the SVM was set at 0.44, 13 (56.5%) of all 23 subjects that responded to BV-therapy could be identified, and at the same threshold, none (0%) of all 31 non-responders would be included (sensitivity 100%, specificity 0%). Conversely, if the threshold is set at 0.75, we would identify 21 (67.7%) of all 31 non-responders with none from the responders (sensitivity 0%, specificity 100%). Thus, by setting upper and lower thresholds, we were capable of identifying those subjects highly likely to not progress and those highly likely to progress. There were 20 (37.0%) subjects that had SVM values between 0.44 and 0.72 and of those, 10 (43.5%) were responders, and 10 (32.3%) were non-responders (sensitivity 50%, specificity 50%). The performance as measured by
the area under the receiver operator characteristic curve for the 6 classifiers ranged from 0.84 to 0.91 for PFS6 and 0.76 to 0.83 for OS. While the SVM performed best for both OS and PFS6, the difference was not significant. We also note here that the variance of the performance across folds was not completely congruent suggesting the performance metrics are/are not reliable. (57%) of subjects highly likely to respond, and 21/31 (68%) of those highly unlikely to respond. Among
PFS6
those that are neither highly likely to respond or not respond, there was a 50% chance of responding. For predicting OS, a threshold of 0.47 predicted 6 who were highly likely to survive long, and a threshold of 0.64 predicted 22 who were highly likely to not survive long. Among the remaining 26 subjects, 62% were long survivors.
Performance of the classifier for predicting OS among all 22 'long survivors' was poorer, in that far more subjects were in the uncertain category. Using a threshold of 0.47, the system identified 6 (27.3%) long survivors with 0 (0%) short survivors (sensitivity 100%, specificity 0%), and a threshold of 0.64 identified 22 (68.8%) short survivors with 0 (0%) long survivors (sensitivity 0%, specificity 100%). Of 26 (48.1%) remaining subjects, 16 (72.7%) were long survivors and 10 (31.3%) were short survivors (sensitivity 62%, specificity 38%).
We found that diffusion and perfusion imaging using an SVM was able to identify 97% of subjects that would respond with an overall accuracy for PFS and OS of 0.82 and 0.78, respectively. The accuracy of the used 6 different classifiers ranged from 0.58 to 0.75 (OS) and 0.69 to 0.81 (PFS). Table 2 shows the results when the SVM threshold was optimized for the binary (2 category) prediction of progression/no progression at 6 months (PFS6) or long/short survival (OS). This demonstrates certain ability to predict but may be less useful in clinical practice when compared to the aforementioned 3 categories that we described above. It also shows less power to predict OS than PFS6. The accuracy of the 6 different classifiers performing binary classification (will respond / won't respond) ranged from 0.58 to 0.75 (OS) and 0.69 to 0.81 (PFS6), respectively. The larger range for OS suggests that the imaging metrics were to a certain extent noisy for predicting OS, which might be not surprising given the numerous other factors that can affect survival.
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Discussion
Recent evidence strongly suggests certain subpopulation of patients harboring recurrent glioblastoma with specific imaging characteristics that may have significant OS benefit from anti-VEGF therapy. Targeted anti-angiogenic therapies are, however, not without substantial cost and even serious toxicities. Bevacizumab is very expensive and treatment cost per patient may be up to 100,000.00US dollars per year. 29 We present a retrospective analysis of novel imaging methods, along with machine learning, to develop noninvasive quantitative prognostic biomarkers for survival and progression on the basis of the combination of Apparent Diffusion Coefficient (ADC) and dynamic-susceptibility contrast (DSC) perfusion MRI-based measurements. Results from the current study confirm that pre-treatment perfusion and diffusion MR-images are predictive imaging biomarkers for both progression-free survival and overall survival benefits in recurrent glioblastoma patients treated with bevacizumab. To our best knowledge, this is the first study using perfusion and diffusion images as well as 6 different classifier techniques to predict likelihood of response of recurrent glioblastoma, particularly with prior treatment using the standard radiation therapy and chemotherapy regimen.
We found that diffusion and perfusion imaging using an SVM was able to identify 97% of subjects that would respond with an overall accuracy for PFS and OS of 0.82 and 0.78, respectively. The accuracy of the used 6 different classifiers ranged from 0.58 to 0.75 (OS) and 0.69 to 0.81 (PFS). Not surprisingly, the imaging metrics were to a certain extent noisy for predicting OS given the numerous other factors that can affect survival rates. If 54 patients in our study are representative of all recurrent glioblastoma subjects, one could select more than two thirds of patients that are highly unlikely to respond to bevacizumab monotherapy. These subjects can benefit from renunciation of bevacizumab therapy that may be associated with rare but potentially serious toxicities.
30, 31
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Our study strictly focuses on metrics at the time of recurrence when BV therapy was contemplated.
Being able to predict the success of BV therapy at the time of recurrence can avoid costs and complications of BV therapy and reduce delay to institute other therapies. Therefore, such a predictor would be of great value. It might also encourage those subjects who have the appropriate imaging findings to pursue antiangiogenic therapy. Importantly, we found that using a combination of diffusion and perfusion, we could predict with high accuracy those subjects that would not likely benefit from BV, and those that likely would benefit from BV. Identifying these 2 subgroups from the full population of recurrent glioblastoma subjects can allowed more precise selection of best therapeutic options.
Of note, we studied 6 different classifier techniques, while most papers have used only 1 machine learning method for the classification task. We feel it is valuable to use several classifiers to help confirm robustness of findings. Given that there was no outlier in terms of performance (e.g. all the classifiers performed rather similarly), we believe the results are likely to be robust. If one or two classifiers were much better or worse than the others, that would suggest the results might be spurious and could cast doubts on the conclusions. Figure 3 shows the rather different decision criteria for PFS6 versus OS and that all classifiers performed worse when predicting OS than PFS6. But given that BV is known to improve PFS6 but not OS, maybe this should not be so surprising. For OS, the total amount of tumor is probably most predictive, and might be reflected in the first decision point -whether there is much tissue without restricted diffusion (e.g. necrosis), they will live long (perhaps with or without BV). But for PFS6, the first decision focuses on how much tumor there is, and amount of restricted diffusion may be a good marker of that. If there is much restricted diffusion, one will likely get a radiographic response, even if there is not an OS benefit.
To our best knowledge, there have not been any published studies using perfusion and diffusion images to predict likelihood of response of recurrent glioblastoma, particularly with prior treatment using the current standard of care (STUPP-regimen). It is worthy of notice that numerous noninvasive imaging techniques have been used to stratify the markers of response and survival using anti-angiogenic treatment in patients with recurrent glioblastoma.
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A N U S C R I P T proposed: adaptive (evasive), in which the tumor acquires the ability to functionally evade the effects of angiogenic blockade, and inherent (intrinsic), which describes primary resistance to antiangiogenic therapy. 45 Potential mechanisms of resistance include upregulation of alternative proangiogenic pathways, leading to revascularization; recruitment of bone marrow-derived proangiogenic cells, thereby precluding the need for VEGF signaling; increased fibrosis and pericyte coverage to provide stabilization to the vessels;
and change to an invasive phenotype to co-opt host vasculature. 45, 46 Historically, the preferred method for assessing radiographic response in high-grade gliomas was based on the Macdonald criteria, which provided a standard measure of tumor response based on the product of the maximal cross-sectional diameters of the contrast-enhanced tumor margins from a disrupted BBB. 47 However, Macdonald criteria has several limitations in the presence of newer therapies. 48, 49 To address some of these limitations, a Response Assessment in Neuro-Oncology Working Group proposed revised response criteria that are more useful for the assessment of antiangiogenic agents. 15 This represents one potential weakness in our results: while survival is quite clear, determining progression at 6 months (PFS6)
can be challenging, particularly with anti-angiogenic therapy. In fact, a number of cases with short OS showed no radiographic progression, even on scans performed just a few weeks before death. For that reason, lack of seeing progression at 6 months is not a reliable outcome. However, the determination that there is progression is much more likely correct, and thus we feel comfortable that our tool's prediction of those likely to progress is reliable.
The advent of anti-angiogenic drugs held great promise as a way to 'starve' tumors by reducing blood flow and neovascularity. However, their value has not been clearly proven for all recurrent glioblastoma patients. In fact, one study of glioblastoma treated with anti-angiogenic agents showed that increased perfusion after initiation of therapy was correlated with longer PFS6 and OS 50 and another report showed that patients new glioblastoma treated with cediranib and chemoradiotherapy did better when they had increased perfusion. 51 Furthermore, in a phase II study of cediranib in patients with recurrent glioblastoma, a decrease in vascular permeability (Ktrans) and an increase in microvessel volume correlated
with OS. 52 However, all of the above mentioned studies focused on changes in perfusion measurements measured before versus after anti-angiogenic therapy was initiated.
A challenge in assessing response to BV in glioma is that it will usually reduce BBB leakage, resulting in less contrast enhancement and edema. This phenomenon is known as pseudoresponse 53 and was observed only sporadically in our subjects. This causes important challenges in confidently identifying those subjects that progressed at 6 months. While antiangiogenics reduce edema, diffusion imaging can still identify tumor progression when enhancement ceases: viable tumor usually restricts diffusion while treated tumor or gliosis tends to have increased diffusion; therefore, an enlarging region of restricted diffusion usually means growth of tumor. The decision tree we propose shows that diffusion imaging is the most important factor in separating subjects (because they are at the top of the tree) but perfusion can help to separate those with less distinctive diffusion measurements.
It is interesting that diffusion was more important for predicting response to an anti-angiogenic agent than perfusion imaging. One might expect that tumors with high perfusion would have the most response potential. In fact, where perfusion was used in the decision tree, low perfusion tumors were more likely to respond, perhaps because the effect of the drug was to largely shut down perfusion to those tumors, while those with much perfusion still had enough blood flow that they were not impacted by BV.
Important limitations of this study include that the calculation of rCBV values is dependent on the software used. 54 While other software can likely also predict non-responsiveness to BV, each package will likely have different values. The software we used has been found to give results very similar to some other packages. The calculation of ADC values is well-known, but differences in filtering of ADC maps will impact histogram values, and thus must also be carefully evaluated when others attempt to replicate our work--we note here that we did not perform any filtering of the images.
Another limitation of this study is due to its retrospective character with only 54 subjects, yet with united BV regimen and steroid dose. The consistency of multiple classifiers helps to improve confidence, but does not guarantee that overfitting did not occur. The thresholds selected for the 3 categories
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(responder/possible/not responder) cannot be expected to be 100% accurate for the general population, and a prospective analysis of this method should be considered.
We also evaluated the various image metrics used by the 6 classifiers that contributed to predictions.
There were substantial differences in the image measurements used between OS and PFS6 prediction for a given machine learning method -e.g., the GB classifier in Figure 2 . One might expect that OS and PFS6 prediction should be related, and the lack of overlap suggests that the image measurements may be noisy, but unrelated biological factors might also account for this difference.
Conclusions
Anti-angiogenic agents appear to be useful only in specific population of patients with recurrent glioblastoma. MRI parameters of ADC and rCBV with the use of machine learning techniques can identify not negligible number of those patients who are highly unlikely to respond to BV therapy. This can be very helpful in selecting patients that either should or should not be treated with BV. Yet, prospective validation of the of the proposed classification approach to eliminate non-responders is warranted.
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